William Samuel David, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electromyography | 16 | 2017 | 1401 | 1.740 |
Why?
|
| Botulism | 2 | 2015 | 21 | 0.970 |
Why?
|
| Amyotrophic Lateral Sclerosis | 16 | 2021 | 1475 | 0.900 |
Why?
|
| Ulnar Neuropathies | 2 | 2012 | 32 | 0.740 |
Why?
|
| Neurophysiology | 1 | 2019 | 145 | 0.590 |
Why?
|
| Nerve Compression Syndromes | 1 | 2019 | 160 | 0.570 |
Why?
|
| Spinal Nerve Roots | 1 | 2017 | 122 | 0.550 |
Why?
|
| Dyspnea | 2 | 2015 | 1352 | 0.550 |
Why?
|
| Myasthenia Gravis | 4 | 2021 | 215 | 0.550 |
Why?
|
| Cystinosis | 3 | 2022 | 26 | 0.540 |
Why?
|
| Neuromuscular Diseases | 3 | 2015 | 260 | 0.530 |
Why?
|
| Muscle, Skeletal | 12 | 2019 | 4978 | 0.510 |
Why?
|
| Muscle Weakness | 9 | 2019 | 412 | 0.510 |
Why?
|
| Neuralgia | 2 | 2019 | 622 | 0.480 |
Why?
|
| Motor Neurons | 5 | 2021 | 870 | 0.470 |
Why?
|
| Peripheral Nervous System Diseases | 5 | 2019 | 716 | 0.450 |
Why?
|
| Muscular Diseases | 5 | 2020 | 553 | 0.420 |
Why?
|
| Myositis, Inclusion Body | 3 | 2021 | 145 | 0.410 |
Why?
|
| Lower Extremity | 2 | 2019 | 1217 | 0.410 |
Why?
|
| Ganglion Cysts | 1 | 2012 | 27 | 0.410 |
Why?
|
| Mononeuropathies | 1 | 2012 | 13 | 0.410 |
Why?
|
| Wrist | 2 | 2019 | 231 | 0.400 |
Why?
|
| Rhabdomyolysis | 1 | 2012 | 150 | 0.360 |
Why?
|
| Quadriceps Muscle | 1 | 2012 | 157 | 0.350 |
Why?
|
| Myography | 3 | 2018 | 111 | 0.340 |
Why?
|
| Simvastatin | 1 | 2012 | 346 | 0.330 |
Why?
|
| Polyneuropathies | 4 | 2022 | 139 | 0.320 |
Why?
|
| Electric Stimulation | 3 | 2011 | 1741 | 0.320 |
Why?
|
| Neurology | 4 | 2022 | 786 | 0.310 |
Why?
|
| Spastic Paraplegia, Hereditary | 2 | 2009 | 171 | 0.310 |
Why?
|
| Deglutition Disorders | 4 | 2022 | 640 | 0.300 |
Why?
|
| Neural Conduction | 5 | 2019 | 443 | 0.280 |
Why?
|
| Evoked Potentials, Motor | 4 | 2018 | 465 | 0.280 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 1437 | 0.280 |
Why?
|
| Hypesthesia | 2 | 2017 | 106 | 0.280 |
Why?
|
| Hereditary Sensory and Autonomic Neuropathies | 2 | 2019 | 41 | 0.280 |
Why?
|
| Superoxide Dismutase | 1 | 2009 | 596 | 0.280 |
Why?
|
| Diagnosis, Differential | 11 | 2019 | 13013 | 0.270 |
Why?
|
| Electric Impedance | 3 | 2018 | 795 | 0.260 |
Why?
|
| Vocal Cord Paralysis | 1 | 2009 | 275 | 0.260 |
Why?
|
| GTP Phosphohydrolases | 1 | 2009 | 525 | 0.260 |
Why?
|
| Immunologic Factors | 3 | 2021 | 1596 | 0.250 |
Why?
|
| Facial Paralysis | 1 | 2009 | 346 | 0.250 |
Why?
|
| Adenosine Triphosphatases | 1 | 2009 | 842 | 0.240 |
Why?
|
| Diagnostic Techniques, Neurological | 2 | 2017 | 62 | 0.240 |
Why?
|
| Electrodiagnosis | 2 | 2003 | 149 | 0.240 |
Why?
|
| Status Asthmaticus | 2 | 2008 | 21 | 0.240 |
Why?
|
| Rabbits | 2 | 2010 | 4773 | 0.230 |
Why?
|
| Distal Myopathies | 2 | 2020 | 18 | 0.220 |
Why?
|
| Muscular Dystrophy, Facioscapulohumeral | 1 | 2023 | 49 | 0.210 |
Why?
|
| Arthrogryposis | 2 | 2019 | 69 | 0.200 |
Why?
|
| Ceftriaxone | 2 | 2014 | 175 | 0.200 |
Why?
|
| Myotonic Dystrophy | 1 | 2023 | 80 | 0.200 |
Why?
|
| Carpal Tunnel Syndrome | 2 | 2003 | 304 | 0.190 |
Why?
|
| Pain | 5 | 2022 | 5099 | 0.190 |
Why?
|
| Phenylenediamines | 1 | 2021 | 89 | 0.180 |
Why?
|
| Myoglobinuria | 1 | 2000 | 22 | 0.170 |
Why?
|
| Radiography, Abdominal | 2 | 2015 | 541 | 0.170 |
Why?
|
| Carbamates | 1 | 2021 | 192 | 0.160 |
Why?
|
| Hereditary Sensory and Motor Neuropathy | 1 | 2019 | 22 | 0.160 |
Why?
|
| Genes, cdc | 1 | 2019 | 113 | 0.160 |
Why?
|
| Tibial Nerve | 1 | 2019 | 55 | 0.160 |
Why?
|
| Lumbosacral Plexus | 1 | 2019 | 53 | 0.160 |
Why?
|
| Fasciculation | 1 | 1998 | 9 | 0.160 |
Why?
|
| Hydroxylamines | 1 | 2018 | 39 | 0.150 |
Why?
|
| Lipodystrophy | 1 | 1999 | 145 | 0.150 |
Why?
|
| Diabetic Neuropathies | 1 | 2022 | 410 | 0.150 |
Why?
|
| Humans | 68 | 2023 | 768171 | 0.140 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 1998 | 132 | 0.140 |
Why?
|
| Creatine | 1 | 2019 | 427 | 0.140 |
Why?
|
| Deficiency Diseases | 1 | 2017 | 74 | 0.140 |
Why?
|
| Tarsal Tunnel Syndrome | 1 | 1996 | 9 | 0.140 |
Why?
|
| Paralysis | 1 | 1998 | 250 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 3251 | 0.140 |
Why?
|
| Double-Blind Method | 11 | 2021 | 12466 | 0.130 |
Why?
|
| Poliomyelitis | 1 | 1997 | 91 | 0.130 |
Why?
|
| Cryoglobulinemia | 1 | 1996 | 84 | 0.130 |
Why?
|
| Neuromuscular Junction Diseases | 1 | 2015 | 14 | 0.130 |
Why?
|
| Peripheral Nervous System | 1 | 2017 | 151 | 0.130 |
Why?
|
| Muscular Dystrophies | 2 | 2015 | 393 | 0.130 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2020 | 302 | 0.130 |
Why?
|
| 4-Aminopyridine | 1 | 2015 | 81 | 0.130 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2020 | 667 | 0.130 |
Why?
|
| Orphan Drug Production | 1 | 2015 | 48 | 0.120 |
Why?
|
| Potassium Channel Blockers | 1 | 2015 | 162 | 0.120 |
Why?
|
| Sample Size | 1 | 2018 | 846 | 0.120 |
Why?
|
| Copper | 1 | 2017 | 368 | 0.120 |
Why?
|
| Sciatic Nerve | 1 | 2019 | 628 | 0.120 |
Why?
|
| Tamoxifen | 1 | 2019 | 966 | 0.120 |
Why?
|
| Action Potentials | 3 | 2011 | 1838 | 0.120 |
Why?
|
| Serine | 1 | 2019 | 831 | 0.120 |
Why?
|
| Arthralgia | 1 | 2019 | 459 | 0.120 |
Why?
|
| Vital Capacity | 5 | 2019 | 996 | 0.120 |
Why?
|
| Spinal Cord Diseases | 1 | 2017 | 291 | 0.120 |
Why?
|
| Middle Aged | 33 | 2021 | 223487 | 0.120 |
Why?
|
| Clozapine | 1 | 1998 | 509 | 0.120 |
Why?
|
| Female | 43 | 2023 | 397187 | 0.120 |
Why?
|
| Cerebrospinal Fluid | 1 | 2017 | 540 | 0.110 |
Why?
|
| Muscular Dystrophies, Limb-Girdle | 1 | 2014 | 62 | 0.110 |
Why?
|
| Hyperlipidemias | 1 | 1999 | 772 | 0.110 |
Why?
|
| Adult | 33 | 2022 | 223646 | 0.110 |
Why?
|
| Zinc | 1 | 2017 | 677 | 0.110 |
Why?
|
| Anti-Asthmatic Agents | 1 | 1998 | 577 | 0.110 |
Why?
|
| Diplopia | 1 | 2015 | 217 | 0.110 |
Why?
|
| Ankle | 1 | 1996 | 353 | 0.110 |
Why?
|
| Voice Disorders | 1 | 1996 | 286 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2019 | 1886 | 0.100 |
Why?
|
| Spinal Cord | 1 | 2021 | 1812 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2017 | 36741 | 0.100 |
Why?
|
| Vasculitis | 1 | 1996 | 525 | 0.100 |
Why?
|
| Ileus | 1 | 2012 | 65 | 0.100 |
Why?
|
| Leg | 2 | 2012 | 1088 | 0.100 |
Why?
|
| Muscle Strength | 3 | 2021 | 640 | 0.100 |
Why?
|
| Sarcoidosis | 1 | 2017 | 535 | 0.100 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 1240 | 0.090 |
Why?
|
| Neuroprotective Agents | 1 | 2018 | 958 | 0.090 |
Why?
|
| Peripheral Nerves | 2 | 2009 | 490 | 0.090 |
Why?
|
| Polysomnography | 1 | 1997 | 1871 | 0.090 |
Why?
|
| Skin | 2 | 2015 | 4505 | 0.090 |
Why?
|
| Airway Remodeling | 1 | 2011 | 133 | 0.090 |
Why?
|
| Aged | 24 | 2021 | 171502 | 0.090 |
Why?
|
| Immunosuppressive Agents | 3 | 2020 | 4206 | 0.090 |
Why?
|
| Hypoglossal Nerve | 1 | 2011 | 110 | 0.090 |
Why?
|
| Male | 36 | 2021 | 364731 | 0.090 |
Why?
|
| Disease Progression | 8 | 2020 | 13668 | 0.090 |
Why?
|
| Anterior Horn Cells | 1 | 2009 | 17 | 0.080 |
Why?
|
| Pain Measurement | 2 | 2019 | 3583 | 0.080 |
Why?
|
| Methotrexate | 1 | 2016 | 1721 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2015 | 1573 | 0.080 |
Why?
|
| Biological Dressings | 1 | 2009 | 30 | 0.080 |
Why?
|
| Biopsy | 3 | 2000 | 6792 | 0.080 |
Why?
|
| Motor Neuron Disease | 1 | 2009 | 98 | 0.080 |
Why?
|
| Photochemistry | 1 | 2009 | 238 | 0.080 |
Why?
|
| Disease Management | 1 | 2019 | 2535 | 0.080 |
Why?
|
| Vaccines | 1 | 1997 | 843 | 0.080 |
Why?
|
| Statistics as Topic | 2 | 2016 | 2357 | 0.080 |
Why?
|
| Abdominal Pain | 1 | 2015 | 1070 | 0.080 |
Why?
|
| Central Nervous System Agents | 1 | 2008 | 73 | 0.080 |
Why?
|
| Valine | 1 | 2009 | 410 | 0.070 |
Why?
|
| Lumbar Vertebrae | 1 | 2017 | 1886 | 0.070 |
Why?
|
| Amnion | 1 | 2009 | 204 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 18065 | 0.070 |
Why?
|
| Receptors, Cholinergic | 2 | 2020 | 244 | 0.070 |
Why?
|
| Syndrome | 2 | 2009 | 3273 | 0.070 |
Why?
|
| Weight Loss | 1 | 2019 | 2721 | 0.070 |
Why?
|
| Deep Sedation | 1 | 2008 | 119 | 0.070 |
Why?
|
| Severity of Illness Index | 5 | 2018 | 15949 | 0.070 |
Why?
|
| Treatment Outcome | 9 | 2021 | 65379 | 0.070 |
Why?
|
| Respiration, Artificial | 3 | 2020 | 2726 | 0.070 |
Why?
|
| Alanine | 1 | 2009 | 614 | 0.070 |
Why?
|
| Chest Wall Oscillation | 1 | 2006 | 16 | 0.070 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2010 | 553 | 0.070 |
Why?
|
| Reference Values | 2 | 2010 | 4939 | 0.070 |
Why?
|
| Muscle Strength Dynamometer | 2 | 2018 | 41 | 0.070 |
Why?
|
| Respiratory Function Tests | 3 | 2019 | 1695 | 0.070 |
Why?
|
| Nerve Fibers | 1 | 2010 | 709 | 0.070 |
Why?
|
| Hepatitis C | 1 | 1996 | 1595 | 0.070 |
Why?
|
| Physical Examination | 1 | 2012 | 1263 | 0.060 |
Why?
|
| Deglutition | 2 | 2022 | 208 | 0.060 |
Why?
|
| Hand Strength | 3 | 2020 | 466 | 0.060 |
Why?
|
| GTP-Binding Proteins | 1 | 2009 | 948 | 0.060 |
Why?
|
| Neurogenesis | 1 | 2011 | 864 | 0.060 |
Why?
|
| Diabetes Complications | 1 | 2012 | 1320 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 2 | 2014 | 7477 | 0.060 |
Why?
|
| Quality Improvement | 2 | 2022 | 3857 | 0.060 |
Why?
|
| Reproducibility of Results | 4 | 2011 | 20225 | 0.060 |
Why?
|
| Mutation | 1 | 2009 | 30237 | 0.060 |
Why?
|
| Antipsychotic Agents | 1 | 1998 | 3081 | 0.060 |
Why?
|
| Cerebral Cortex | 1 | 2021 | 5812 | 0.060 |
Why?
|
| Melanoma | 1 | 2023 | 5706 | 0.060 |
Why?
|
| Prednisone | 2 | 2021 | 1567 | 0.060 |
Why?
|
| Tuberculosis | 1 | 2017 | 2029 | 0.060 |
Why?
|
| Nervous System Diseases | 1 | 2015 | 1662 | 0.060 |
Why?
|
| Phenotype | 2 | 2019 | 16726 | 0.060 |
Why?
|
| Electrophysiology | 2 | 1996 | 1266 | 0.050 |
Why?
|
| Disability Evaluation | 2 | 2011 | 1835 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 5891 | 0.050 |
Why?
|
| Sarcoma | 1 | 1994 | 1806 | 0.050 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 59626 | 0.050 |
Why?
|
| Nerve Regeneration | 1 | 2009 | 797 | 0.050 |
Why?
|
| Barium | 1 | 2022 | 62 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3115 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3238 | 0.050 |
Why?
|
| Fructose | 1 | 2003 | 284 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2009 | 4120 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2008 | 1942 | 0.050 |
Why?
|
| Breathing Exercises | 1 | 2020 | 59 | 0.040 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2000 | 64 | 0.040 |
Why?
|
| Respiration | 1 | 2006 | 1665 | 0.040 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2022 | 430 | 0.040 |
Why?
|
| Research Design | 2 | 2013 | 6209 | 0.040 |
Why?
|
| Respiratory Aspiration | 1 | 2020 | 89 | 0.040 |
Why?
|
| Time | 1 | 2021 | 552 | 0.040 |
Why?
|
| Ulnar Nerve | 1 | 1999 | 104 | 0.040 |
Why?
|
| Retrospective Studies | 9 | 2023 | 81760 | 0.040 |
Why?
|
| Serine C-Palmitoyltransferase | 1 | 2019 | 42 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2014 | 4310 | 0.040 |
Why?
|
| Median Nerve | 1 | 1999 | 133 | 0.040 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 39354 | 0.040 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2011 | 1899 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 7454 | 0.040 |
Why?
|
| Vitamin E Deficiency | 1 | 2017 | 30 | 0.040 |
Why?
|
| Kidney Tubules | 1 | 2000 | 454 | 0.040 |
Why?
|
| Physicians | 1 | 2015 | 4598 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 9262 | 0.040 |
Why?
|
| Sphingolipids | 1 | 2019 | 178 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 1998 | 313 | 0.030 |
Why?
|
| Adolescent | 9 | 2019 | 89169 | 0.030 |
Why?
|
| Young Adult | 7 | 2020 | 60066 | 0.030 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 418 | 0.030 |
Why?
|
| Sural Nerve | 1 | 1996 | 105 | 0.030 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2017 | 119 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2019 | 914 | 0.030 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2017 | 246 | 0.030 |
Why?
|
| Time Factors | 7 | 2012 | 40220 | 0.030 |
Why?
|
| Phonetics | 1 | 1996 | 204 | 0.030 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2019 | 465 | 0.030 |
Why?
|
| Botulinum Toxins | 1 | 1996 | 191 | 0.030 |
Why?
|
| Genotype | 1 | 2009 | 13045 | 0.030 |
Why?
|
| Sensation | 1 | 1996 | 336 | 0.030 |
Why?
|
| Smad2 Protein | 1 | 2014 | 144 | 0.030 |
Why?
|
| Smad3 Protein | 1 | 2014 | 166 | 0.030 |
Why?
|
| Antibodies, Blocking | 1 | 2014 | 250 | 0.030 |
Why?
|
| Hand | 1 | 2019 | 913 | 0.030 |
Why?
|
| Extremities | 1 | 2019 | 870 | 0.030 |
Why?
|
| Activin Receptors, Type II | 1 | 2014 | 122 | 0.030 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 2015 | 102 | 0.030 |
Why?
|
| Patients | 1 | 2020 | 908 | 0.030 |
Why?
|
| Thigh | 1 | 2014 | 239 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2000 | 1880 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2016 | 948 | 0.030 |
Why?
|
| Elbow | 1 | 1993 | 130 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 1997 | 1148 | 0.030 |
Why?
|
| Half-Life | 1 | 2014 | 651 | 0.030 |
Why?
|
| Positive-Pressure Respiration | 1 | 1997 | 713 | 0.030 |
Why?
|
| Accidental Falls | 1 | 2021 | 1080 | 0.030 |
Why?
|
| Spinal Muscular Atrophies of Childhood | 1 | 1994 | 116 | 0.030 |
Why?
|
| Accidents | 1 | 1993 | 164 | 0.030 |
Why?
|
| Genetic Linkage | 1 | 1998 | 2342 | 0.030 |
Why?
|
| Reaction Time | 1 | 1999 | 2101 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2020 | 1628 | 0.030 |
Why?
|
| Foot | 1 | 1996 | 576 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2009 | 7876 | 0.030 |
Why?
|
| Functional Laterality | 1 | 1999 | 2264 | 0.030 |
Why?
|
| Fluoroscopy | 1 | 1996 | 947 | 0.030 |
Why?
|
| Pain Threshold | 1 | 2016 | 606 | 0.030 |
Why?
|
| Infant | 4 | 2003 | 36535 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 12252 | 0.030 |
Why?
|
| Hyperalgesia | 1 | 2016 | 527 | 0.020 |
Why?
|
| Vocal Cords | 1 | 1996 | 520 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2016 | 1643 | 0.020 |
Why?
|
| Intubation, Intratracheal | 1 | 2020 | 1359 | 0.020 |
Why?
|
| Arousal | 1 | 1997 | 1180 | 0.020 |
Why?
|
| Triglycerides | 1 | 1999 | 2464 | 0.020 |
Why?
|
| Forearm | 1 | 1993 | 427 | 0.020 |
Why?
|
| Anticonvulsants | 1 | 2021 | 1923 | 0.020 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 8052 | 0.020 |
Why?
|
| Canada | 1 | 2016 | 2130 | 0.020 |
Why?
|
| Brain | 1 | 2017 | 27362 | 0.020 |
Why?
|
| Pandemics | 2 | 2020 | 8747 | 0.020 |
Why?
|
| Cholesterol | 1 | 1999 | 2914 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2014 | 2300 | 0.020 |
Why?
|
| Treatment Failure | 2 | 2008 | 2661 | 0.020 |
Why?
|
| Psychometrics | 1 | 2019 | 3063 | 0.020 |
Why?
|
| Thromboembolism | 2 | 2008 | 1004 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2018 | 10099 | 0.020 |
Why?
|
| Organ Size | 1 | 2014 | 2267 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2014 | 2230 | 0.020 |
Why?
|
| Gastric Bypass | 1 | 2017 | 824 | 0.020 |
Why?
|
| Peroneal Nerve | 1 | 2009 | 80 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 10763 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2000 | 2907 | 0.020 |
Why?
|
| ROC Curve | 1 | 2016 | 3628 | 0.020 |
Why?
|
| Tongue | 1 | 2011 | 406 | 0.020 |
Why?
|
| Demography | 1 | 2013 | 1641 | 0.020 |
Why?
|
| Quality of Life | 2 | 2006 | 13490 | 0.020 |
Why?
|
| Self Report | 1 | 2019 | 3773 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2016 | 2121 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2008 | 687 | 0.020 |
Why?
|
| Adjustment Disorders | 1 | 2006 | 68 | 0.020 |
Why?
|
| Exercise Test | 1 | 2014 | 2186 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2006 | 6873 | 0.020 |
Why?
|
| Data Collection | 1 | 2015 | 3326 | 0.020 |
Why?
|
| Occupational Diseases | 1 | 1993 | 1457 | 0.020 |
Why?
|
| Marriage | 1 | 2006 | 351 | 0.010 |
Why?
|
| Tracheostomy | 1 | 2008 | 430 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2014 | 8316 | 0.010 |
Why?
|
| Cohort Studies | 3 | 2018 | 41753 | 0.010 |
Why?
|
| Life Tables | 1 | 2003 | 367 | 0.010 |
Why?
|
| Registries | 1 | 2019 | 8375 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1996 | 11095 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 3706 | 0.010 |
Why?
|
| Models, Animal | 1 | 2009 | 2122 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 26379 | 0.010 |
Why?
|
| Sleep | 1 | 1997 | 4818 | 0.010 |
Why?
|
| United States | 2 | 2022 | 73039 | 0.010 |
Why?
|
| Animals | 2 | 2010 | 169285 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 3436 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2003 | 26421 | 0.010 |
Why?
|
| Child, Preschool | 2 | 1999 | 42669 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 1159 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2003 | 1209 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2009 | 2981 | 0.010 |
Why?
|
| Bayes Theorem | 1 | 2006 | 2359 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 6525 | 0.010 |
Why?
|
| Survival Rate | 1 | 2012 | 12840 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1998 | 286 | 0.010 |
Why?
|
| Asthma | 1 | 1996 | 6291 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 1998 | 361 | 0.010 |
Why?
|
| Pancuronium | 1 | 1996 | 44 | 0.010 |
Why?
|
| Social Support | 1 | 2006 | 2193 | 0.010 |
Why?
|
| Vecuronium Bromide | 1 | 1996 | 33 | 0.010 |
Why?
|
| Atracurium | 1 | 1996 | 51 | 0.010 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 1996 | 145 | 0.010 |
Why?
|
| Albuterol | 1 | 1996 | 211 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1996 | 386 | 0.010 |
Why?
|
| Child | 2 | 1999 | 80917 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2011 | 22290 | 0.010 |
Why?
|
| Bronchodilator Agents | 1 | 1996 | 518 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1998 | 2603 | 0.010 |
Why?
|
| Anxiety | 1 | 2006 | 4672 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2006 | 4530 | 0.010 |
Why?
|
| Pedigree | 1 | 1998 | 4539 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 15453 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2003 | 12543 | 0.000 |
Why?
|
| Glucocorticoids | 1 | 1996 | 2167 | 0.000 |
Why?
|
| Risk Factors | 2 | 2008 | 74944 | 0.000 |
Why?
|
| Acute Disease | 1 | 1996 | 7243 | 0.000 |
Why?
|
| Incidence | 1 | 1996 | 21538 | 0.000 |
Why?
|